Fusion Glycoprotein Vaccine for Human Metapneumovirus: Licensing Opportunity

Investigators at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have generated an hMPV fusion glycoprotein (“F protein”) stabilized in a prefusion conformation. The prefusion stabilized F protein immunogen can be delivered as either an isolated homotrimer or trimers displayed on a nanoparticle. These immunogens elicit broad and potent hMPV-neutralizing antibodies.

Human metapneumovirus (hMPV), a negative, single-stranded RNA virus, accounts for approximately 5-15% of infant respiratory tract infections and poses a severe risk of disease and hospitalization in both the elderly and the immunocompromised.  Investigators at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have generated an hMPV fusion glycoprotein (“F protein”) stabilized in a prefusion conformation.

Stabilizing this prefusion conformation of the F protein reveals an immunodominant site which makes it an ideal vaccine immunogen.  The prefusion stabilized F protein immunogen can be delivered as either an isolated homotrimer or trimers displayed on a nanoparticle. These immunogens elicit broad and potent hMPV-neutralizing antibodies.      

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404.

Potential Commercial Applications: 

  • Vaccine for prevention of human metapneumovirus infection

Competitive Advantages: 

  • No human metapneumovirus vaccine is currently available

Development Stage:

  • In vitro data available

  • In vivo animal data available

Inventors:   Peter D. Kwong, (NIAID), Michael Gordon Joyce (NIAID), Peter L. Collins (NIAID), Ursula J. Buchholz (NIAID), Guillaume Stewart-Jones (NIAID), Baoshan Zhang (NIAID), Yongping Yang (NIAID), Davide Corti (Institute for Research in Biomedicine), Antonio Lanzavecchia (Institute for Research in Biomedicine)

Intellectual Property:
US Application No. 62/096,744
PCT Application No. PCT/IB2015/059991
US Application No. 15/539,640
EP Application No. 15831073.

Licensing Contact: Dr. Vince Contreras, 240-669-2823; vince.contreras@nih.gov.

Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).

No comments yet.